AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01110-06v1
50/12/4191    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kosowska-Shick, K.
Right arrow Articles by Appelbaum, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kosowska-Shick, K.
Right arrow Articles by Appelbaum, P. C.
Antimicrobial Agents and Chemotherapy, December 2006, p. 4191-4194, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.01110-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Activity of DX-619 Compared to Other Agents against Viridans Group Streptococci, Streptococcus bovis, and Cardiobacterium hominis{triangledown}

Klaudia Kosowska-Shick,1 Kathy Smith,1 Tatiana Bogdanovich,1 Lois M. Ednie,1 Ronald N. Jones,2 and Peter C. Appelbaum1*

Hershey Medical Center, Hershey, Pennsylvania 17033,1 JMI Laboratories, North Liberty, Iowa 523172

Received 1 September 2006/ Returned for modification 19 September 2006/ Accepted 19 September 2006

Against 198 viridans group streptococci, 25 Streptococcus bovis strains, and 5 Cardiobacterium hominis strains, MICs of DX-619, a des-F(6)-quinolone, were between 0.004 and 0.25 µg/ml. These MICs were lower than those of other quinolones (≤0.008 to >32 µg/ml). ß-Lactam MICs were between ≤0.008 and 16 µg/ml. Azithromycin resistance was found in most species, while most were telithromycin susceptible. Glycopeptides and linezolid were active against viridans group strains but inactive against C. hominis.

* Corresponding author. Mailing address: Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail: pappelbaum{at}psu.edu.

{triangledown} Published ahead of print on 16 October 2006.

Antimicrobial Agents and Chemotherapy, December 2006, p. 4191-4194, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.01110-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.